These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 1385047)

  • 1. Decay accelerating factor (CD55).
    Nicholson-Weller A
    Curr Top Microbiol Immunol; 1992; 178():7-30. PubMed ID: 1385047
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of transfected MACIF (CD59) on complement-mediated swine endothelial cell lysis, compared with those of membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
    Miyagawa S; Shirakura R; Nakata S; Izutani H; Matsuda H; Iwata K; Nagasawa S; Terado A; Hatanaka M; Matsumoto M
    Transplant Proc; 1995 Feb; 27(1):328-9. PubMed ID: 7533401
    [No Abstract]   [Full Text] [Related]  

  • 3. Evidence that double transfection to xenoendothelial cells using GPI-anchoring complement regulatory factor (decay-accelerating factor and homologous restriction factor 20) gene is useful for the inhibition of human complement-mediated cytolysis.
    Hayashi S; Isobe K; Emi N; Okada H; Yasutomi M; Negita M; Koike C; Uchida K; Yokoyama I; Takagi H
    Transplant Proc; 1995 Feb; 27(1):330. PubMed ID: 7533402
    [No Abstract]   [Full Text] [Related]  

  • 4. Protection of mammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay-accelerating factor.
    Oglesby TJ; White D; Tedja I; Liszewski K; Wright L; Van den Bogarde J; Atkinson JP
    Trans Assoc Am Physicians; 1991; 104():164-72. PubMed ID: 1726964
    [No Abstract]   [Full Text] [Related]  

  • 5. A partial cDNA clone of trypomastigote decay-accelerating factor (T-DAF), a developmentally regulated complement inhibitor of Trypanosoma cruzi, has genetic and functional similarities to the human complement inhibitor DAF.
    Tambourgi DV; Kipnis TL; da Silva WD; Joiner KA; Sher A; Heath S; Hall BF; Ogden GB
    Infect Immun; 1993 Sep; 61(9):3656-63. PubMed ID: 7689538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Membrane inhibitor of reactive lysis.
    Holguin MH; Parker CJ
    Curr Top Microbiol Immunol; 1992; 178():61-85. PubMed ID: 1385046
    [No Abstract]   [Full Text] [Related]  

  • 7. Tissue expression of human decay accelerating factor, a regulator of complement activation expressed in mice: a potential approach to inhibition of hyperacute xenograft rejection.
    Cary N; Moody J; Yannoutsos N; Wallwork J; White D
    Transplant Proc; 1993 Feb; 25(1 Pt 1):400-1. PubMed ID: 7679815
    [No Abstract]   [Full Text] [Related]  

  • 8. Relative roles of hCD46 and hCD55 in the regulation of hyperacute rejection.
    Verbakel CA; Bonthuis F; Eerhart SE; van Dixhoorn M; Grosveld F; Marquet RL; IJzermans JN
    Transplant Proc; 2000 Aug; 32(5):903-4. PubMed ID: 10936266
    [No Abstract]   [Full Text] [Related]  

  • 9. Permanent expression of human CD59 and/or decay-accelerating factor by rat endothelial cells confers protection from human complement-mediated lysis.
    Charreau B; Cassard A; Tesson L; Le Mauff B; Blanchard D; Lublin D; Soulillou JP; Anegon I
    Transplant Proc; 1995 Feb; 27(1):336-7. PubMed ID: 7533404
    [No Abstract]   [Full Text] [Related]  

  • 10. Mice transgenic for human CD46 and CD55 are protected from human complement attack.
    Mulder LC; Mora M; Ciccopiedi E; Melli C; Nuti S; Marinucci G; Bruzzone P; Lazzeri M; Lorenzini R; Alfani D
    Transplant Proc; 1995 Feb; 27(1):333-5. PubMed ID: 7533403
    [No Abstract]   [Full Text] [Related]  

  • 11. [Complement regulatory proteins].
    Miyagawa S
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():274-8. PubMed ID: 15861668
    [No Abstract]   [Full Text] [Related]  

  • 12. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities.
    Higgins PJ; Ko JL; Lobell R; Sardonini C; Alessi MK; Yeh CG
    J Immunol; 1997 Mar; 158(6):2872-81. PubMed ID: 9058824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of human decay accelerating factor in transgenic pigs.
    Cozzi E; Langford GA; Richards A; Elsome K; Lancaster R; Chen P; Yannoutsos N; White DJ
    Transplant Proc; 1994 Jun; 26(3):1402-3. PubMed ID: 7518135
    [No Abstract]   [Full Text] [Related]  

  • 14. Paroxysmal nocturnal hemoglobinuria and glycosyl phosphatidylinositol anchored proteins that regulate complement.
    Parker CJ
    Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):36-42. PubMed ID: 1718642
    [No Abstract]   [Full Text] [Related]  

  • 15. Adenovirus-mediated gene transfer of the triple human complement regulating proteins (DAF, CD59, MCP) in xenogeneic pig liver perfusion.
    Shiraishi M; Nagahama M; Nozato E; Oshiro T; Taira K; Muto Y
    Transplant Proc; 2000 Aug; 32(5):1116-7. PubMed ID: 10936387
    [No Abstract]   [Full Text] [Related]  

  • 16. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack.
    Brodbeck WG; Mold C; Atkinson JP; Medof ME
    J Immunol; 2000 Oct; 165(7):3999-4006. PubMed ID: 11034410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of pigs transgenic for human decay accelerating factor.
    Langford GA; Yannoutsos N; Cozzi E; Lancaster R; Elsome K; Chen P; Richards A; White DJ
    Transplant Proc; 1994 Jun; 26(3):1400-1. PubMed ID: 7518134
    [No Abstract]   [Full Text] [Related]  

  • 18. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decay-accelerating factor and membrane cofactor protein.
    Lublin DM; Atkinson JP
    Curr Top Microbiol Immunol; 1990; 153():123-45. PubMed ID: 1688754
    [No Abstract]   [Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1 incorporates both glycosyl phosphatidylinositol-anchored CD55 and CD59 and integral membrane CD46 at levels that protect from complement-mediated destruction.
    Saifuddin M; Hedayati T; Atkinson JP; Holguin MH; Parker CJ; Spear GT
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1907-11. PubMed ID: 9266986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.